Resolution regarding the adoption of the income statement and the balance sheet as well as consolidated income statement and consolidated balance sheet, appropriation of result and discharge from liability.
The Annual General Meeting resolved to adopt the income statement and balance sheet, consolidated income statement and balance sheet for 2023. Furthermore, it was resolved that the company's results shall be carried forward and thus no dividend will be distributed. The Annual General Meeting also resolved to discharge the members of the Board of Directors and Chief Executive Officer from liability.
The number of members of the Board of Directors and auditors, election of the Board of Directors and auditor and remuneration to the Board of Directors and the auditor
The Annual General Meeting resolved that the members of the Board of Directors shall be seven with no deputy members.
The Annual General Meeting resolved on re-election of
The Annual General Meeting resolved to re-elect
The Annual General Meeting resolved that the fees for the Board of Directors, for the period until the end of the next Annual General Meeting, shall remain unchanged from the previous year and shall be
Resolution regarding principles for the appointment of the nomination committee
The Annual General Meeting resolved to adopt the proposed principles for appointment of the Nomination Committee.
Approval of the Board of Directors' remuneration report
The Annual General meeting approved the Board of Directors' remuneration report.
Resolution to adopt a long-term incentive program based on performance-based share rights for employees at
The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to adopt a long-term incentive program based on performance-based share rights for employees of the
Resolution to adopt a long-term incentive program based on employee stock options for employees in
The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to adopt a long-term incentive program for employees in
Resolution to authorize the Board of Directors to resolve on issue of ordinary shares and warrants and/or convertibles
The Annual General Meeting further resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to, until the next Annual General Meeting, on one or more occasions, decide upon issuances of new ordinary shares, warrants and/or convertibles. New issues of ordinary shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise on specific terms. The number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, may not correspond to a dilution of more than twenty per cent of the total number of shares outstanding at the Annual General Meeting's resolution on the authorization, after full exercise of the authorization. In the current position of the company, it is of high importance for the company's ability to build and maximize shareholder value to have, and it is the purpose of the proposed authorization to provide, sufficient financial flexibility and a broad acting scope for the Board of Directors, in particular to match significant commercial and pipeline growth acceleration opportunities with the available financing mandate, provide flexibility to quickly respond to strategic opportunities such as partnerships or collaborations or to expand the shareholder constituency in certain investor markets or in connection with the listing of the shares on a
Resolution to amend the articles of association
The Annual General Meeting further resolved, in accordance with the Board of Directors' proposal, to amend the articles of association whereby the limits for the share capital and the number of shares are increased.
More information about the resolutions is available in the notice and the complete propisals which are available on the company's website, www.hansabiopharma.com.
The information was submitted for publication, through the agency of the contact person set out below, at 15:00 CEST on
--- ENDS ---
Contacts for more information:
IR@hansabiopharma.com
media@hansabiopharma.com
Notes to editors
About
©2024 Hansa Biopharma AB.
https://news.cision.com/hansa-biopharma-ab/r/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab--publ-,c4007570
https://mb.cision.com/Main/1219/4007570/2889581.pdf
(c) 2024 Cision. All rights reserved., source